Kim Breuss
study nurse
Medizinische Onkologie und Hämatologie · Dept. I
CAR T- Cell Register
Jul 30, 2021EBMT Registry data processing framework
Clinical Studies - Jul 30, 2021 - Dec 31, 2026
Ongoing
Project leader: Fehr Martin
Members: Breuss Kim, Müller Fiona
A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR-mutant non-small cell lung carcinoma with acquired resistance ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant non-small cell lung carcinoma
Jul 22, 2020
Clinical Studies - Jul 22, 2020 - Aug 30, 2028
Completed
Project leader: Frueh Martin
Members: Breuss Kim, Quinter Janine
Beat-meso ETOP 13-18
Jun 20, 2019A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma
Clinical Studies - Jun 20, 2019 - Dec 31, 2099
Ongoing
Project leader: Früh Martin
Members: Breuss Kim, Müller Fiona
A 24 weeks activity program in patients with early breast cancer receiving aromatase inhibitor therapy. A multicenter randomized phase III trial.
Jun 17, 2019
Clinical Studies - Jun 17, 2019 - Jun 21, 2023
Completed
Project leader: Rordorf Tamara
Members: Breuss Kim, Quinter Janine
Trial SAKK 19/17: First line durvalumab in patients with PD-L1 positve, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial
Oct 23, 2018Lung cancer is the leading cause of cancer deaths. An estimated 30 to 40% of patients diagnosed with NSCLC have a poor PS defined as a score of 2 or higher on the ECOG scale. PS 2 patients are often underrepresented in clinical trials despite represe...
Clinical Studies - Oct 23, 2018 - Dec 31, 2099
Ongoing
Project leader: Früh Martin
Members: Breuss Kim, Quinter Janine
SAKK 06/17
May 22, 2018Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A Multicenter, Single-arm Phase II Trial.
Clinical Studies - May 22, 2018 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Breuss Kim, Müller Fiona
SAKK 07/17
Jan 4, 2018Nivolumab in combination with Ipilimumab in patients with metastatic renal cell carcinoma: A multicentre single-arm phase lI trial.
Clinical Studies - Jan 4, 2018 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Breuss Kim, Müller Fiona
SAKK HD 21
Jun 9, 2017Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD.
Clinical Studies - Jun 9, 2017 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Breuss Kim, Müller Fiona
Anti-PD-L1 antibody MEDI4736 in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
Apr 22, 2016
Clinical Studies - Apr 22, 2016 - Aug 28, 2024
Completed
Project leader: Frueh Martin
Members: Breuss Kim, Quinter Janine